SUBSCRIBE
SUBSCRIBE
News   Policy

U.S. FDA Panel Rejects FDA and Genentech (South SF)'s (JOBS) Xolair Asthma Drug for Children

November 19, 2009 | 
1 min read
Bookmark and Share

Reuters -- Roche and Novartis's asthma drug Xolair should not be approved for children aged 6 to 11, a U.S. advisory panel decided on Wednesday.
Regulatory
Genentech, Inc.
MORE ON THIS TOPIC
People group with speech bubbles. Banner concept of business, internet discuss, news, social networks, chat, dialogue.
Regulatory
Rare disease reform, CMC risk, reshoring US trials top of mind ahead of PDUFA VIII meeting
September 15, 2026
 · 
6 min read
 · 
Heather McKenzie
Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus. 3d rendering
IN PARTNERSHIP WITH VIVA BIOTECH
Cyclic peptides open new drug frontiers, if manufacturing can keep up
September 14, 2026
 · 
6 min read
 · 
Jennifer C. Smith-Parker
Creative background as a blue abstract extreme perspective design element representing time travel or Psychedelic and hallucinogenic consciousness trip as a 3D illustration.
Psychedelics
Psychedelic therapies ride wave of public favor into FDA hearing
September 14, 2026
 · 
3 min read
 · 
Michael Gibney
A lighthouse providing guidance to a boat in a sea of red tape. The lighthouse, man & boat, and the red tape are on a separate labeled layer from the background.
Editorial
Mikhail, Davis embody the FDA’s stabilization, Seehafer signals AI revolution is coming
September 11, 2026
 · 
5 min read
 · 
Jef Akst